Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,166 across all filing types
Latest filing 2025-08-12 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin Announces Licensing Deal for Ranibizumab Biosimilar.
Regulatory Filings Classification · 95% confidence The document is a press release announcing a licensing deal between Lupin Limited and Sandoz Group AG for the commercialization of a biosimilar drug. It is addressed to stock exchanges and references a disclosure pursuant to a listing obligation regulation. The content focuses on a partnership and commercial agreement rather than financial results, management changes, or regulatory filings. The document is relatively short (4712 characters) and does not contain financial statements or detailed financial data. It is an announcement of a corporate development rather than a report or regulatory filing. Therefore, it best fits the category of a Regulatory Filing (RNS), which is a fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2025-08-12 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a licensing deal between Lupin Limited and Sandoz Group AG for the commercialization of a biosimilar drug. It is addressed to stock exchanges and references a disclosure pursuant to a listing obligation regulation. The content focuses on a partnership and commercial agreement rather than financial results, management changes, or regulatory filings. The document is relatively short (4712 characters) and serves as an announcement of a corporate development rather than a detailed financial or regulatory report. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including partnership and commercialization agreements that impact company operations and market presence.
2025-08-12 English
Completion of term of Mr. Jean-Luc Belingard as an Independent Director of the Company.
Board/Management Information Classification · 100% confidence The document is a formal disclosure under Regulation 30 of the SEBI Listing Regulations regarding the cessation of an Independent Director's term. It details the completion of Mr. Jean-Luc Belingard's second term as an Independent Director and his consequent cessation. The document includes regulatory references and a structured annexure with particulars about the change. There are no financial statements, earnings data, or report attachments. The content is focused on management/board changes, specifically the end of a director's term. Therefore, this fits the category of Board/Management Information (MANG). The document length is 3311 characters, which is consistent with a detailed announcement rather than a full report or a brief notice.
2025-08-11 English
Change in Director(s)
Board/Management Information Classification · 100% confidence The document is a formal disclosure under Regulation 30 of the SEBI Listing Regulations regarding the cessation of Mr. Jean-Luc Belingard as an Independent Director after completing his second term. It includes details about the director's term completion and official appreciation but does not contain financial data, audit information, or report content. The document is an announcement about a change in the company's board of directors, specifically the end of a director's term. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3311 characters, which is consistent with a brief announcement rather than a full report.
2025-08-11 English
Details of Voting Results of Forty-Third Annual General Meeting of the Company and Consolidated Scrutinizer''s Report.
Regulatory Filings
2025-08-11 English
Shareholders meeting
Regulatory Filings
2025-08-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.